Minetta C Liu MD

Oncology•Rochester, MN

Mayo Clinic

Join to View Full Profile

200 1st St SwRochester, MN 55905
Phone+1 507-284-2511

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1995

Certifications & Licensure

MN State Medical License 2013 - 2024
DC State Medical License 1997 - 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer Start of enrollment: 2001 Apr 01
Terminated
Phase 2
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer Start of enrollment: 2000 Oct 01
Completed
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
RECRUITING
PHASE2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
SUSPENDED
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice Start of enrollment: 2019 Dec 12
Completed
Not Applicable
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer Start of enrollment: 2020 Sep 23
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

1 citations
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Otto Metzger Filho, Karla Ballman, Jordan Campbell, Minetta Liu, Jennifer Ligibel
Journal of Clinical Oncology. 2025-04-01
4 citations
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
John P Sfakianos, Arnab Basu, George Laliotis, Shivaram Cumarasamy, Jordan M Rich
European Urology Oncology. 2025-04-01
Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli
Clinical Cancer Research. 2025-03-18

Abstracts/Posters

Molecular Alterations in Adult Histiocytic Neoplasms
Minetta C Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.
2019 ASCO Annual Meeting - 6/1/2019
Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Applications of Liquid Biopsies in Metastatic Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

First of Its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall SurvivalSeptember 14th, 2024
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall SurvivalSeptember 8th, 2024
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual MeetingApril 14th, 2023
Join now to see all

Committees

Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present